# US 9,751,933 B2 · Antibody specific for CLEC14A and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,751,933 B2
- Document ID: US9751933B2
- Status: Granted
- Kind: B2
- Application number: 14/407,756
- Filed: 2013-06-14
- Published: 2015-05-21
- Granted: 2017-09-05
- Earliest claimed: 2012-06-14
- Assignees: Scripps Korea Antibody Institute
- Applicants: Scripps Korea Antibody Institute
- Inventors: Suk Mook Lee; Min kyoung Ki; Mee Hyun Jeoung; Jong Rip Choi
- Web page: https://patentgrep.com/patent/US9751933B2

## CPC

- C07K 16/18: against material from animals or humans
- A61K 47/6843: {the antibody targeting a material from animals or humans}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 13/12: of the kidneys
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/06: Antipsoriatics
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 14/435: from animals; from humans
- C07K 14/7056: {Lectin superfamily, e.g. CD23, CD72}
- C07K 16/2851: {against the lectin superfamily, e.g. CD23, CD72}
- G01N 33/53: Immunoassay; Biospecific binding assay; Materials therefor
- C07K 2317/21: from primates, e.g. man
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Provided is an antibody specifically binding to the CTLD (C-type lectin like domain) of clec14a (C-type lectin domain family 14, member A), a method for preparing the antibody, a composition for suppressing angiogenesis comprising the antibody, a method for suppressing angiogenesis by administering the antibody or the composition, a composition for preventing or treating cancer comprising the antibody, a method for treating cancer by administering the antibody or the composition, a composition for diagnosing cancer comprising the antibody, a kit for diagnosing cancer comprising the composition, a method for diagnosing cancer using the composition, a composition for suppressing angiogenesis comprising a material for inhibiting expression of clec14a, a kit for angiogenesis comprising the composition, a method for suppressing angiogenesis or treating cancer using the composition, and the use of the CTLD of clec14a as an epitope for an antibody suppressive of angiogenesis.

## Claims

### Claim 1

An antibody, binding specifically to CTLD (C-type lectin like domain) of clec14a (C-type lectin domain family 14, member A), wherein the antibody comprises at least one selected from the group consisting of:
(a) a heavy-chain variable region comprising heavy-chain CDR1 defined by an amino acid sequence of SEQ ID NO: 14, heavy-chain CDR2 defined by an amino acid sequence of SEQ ID NO: 16, and heavy-chain CDR3 defined by an amino acid sequence of SEQ ID NO: 18, and a light-chain variable region comprising light-chain CDR1 defined by an amino acid sequence of SEQ ID NO: 42, light-chain CDR2 defined by an amino acid sequence of SEQ ID NO: 44, and light-chain CDR3 defined by an amino acid sequence of SEQ ID NO: 46;
(b) a heavy-chain variable region comprising heavy-chain CDR1 defined by an amino acid sequence of SEQ ID NO: 21, heavy-chain CDR2 defined by an amino acid sequence of SEQ ID NO: 23, and heavy-chain CDR3 defined by an amino acid sequence of SEQ ID NO: 25, and a light-chain variable region comprising light-chain CDR1 defined by an amino acid sequence of SEQ ID NO: 49, light-chain CDR2 defined by an amino acid sequence of SEQ ID NO: 51, and light-chain CDR3 defined by an amino acid sequence of SEQ ID NO: 53;
(c) a heavy-chain variable region comprising heavy-chain CDR1 defined by an amino acid sequence of SEQ ID NO: 28, heavy-chain CDR2 defined by an amino acid sequence of SEQ ID NO: 30, and heavy-chain CDR3 defined by an amino acid sequence of SEQ ID NO: 32, and a light-chain variable region comprising light-chain CDR1 defined by an amino acid sequence of SEQ ID NO: 56, light-chain CDR2 defined by an amino acid sequence of SEQ ID NO: 58, and light-chain CDR3 defined by an amino acid sequence of SEQ ID NO: 60; and
(d) a heavy-chain variable region comprising heavy-chain CDR1 defined by an amino acid sequence of SEQ ID NO: 35, heavy-chain CDR2 defined by an amino acid sequence of SEQ ID NO: 37, and heavy-chain CDR3 defined by an amino acid sequence of SEQ ID NO: 39, and a light-chain variable region comprising light-chain CDR1 defined by an amino acid sequence of SEQ ID NO: 63, light-chain CDR2 defined by an amino acid sequence of SEQ ID NO: 65, and light-chain CDR3 defined by an amino acid sequence of SEQ ID NO: 67.

### Claim 2 (depends on 1)

The antibody of claim 1, wherein the antibody is selected from the group consisting of:
an antibody comprising a heavy-chain variable region having an amino acid sequence of SEQ ID NO: 125 and a light-chain variable region having an amino acid sequence of SEQ ID NO: 129;
an antibody comprising a heavy-chain variable region having an amino acid sequence of SEQ ID NO: 126 and a light-chain variable region having an amino acid sequence of SEQ ID NO: 130;
an antibody comprising a heavy-chain variable region having an amino acid sequence of SEQ ID NO: 127 and a light-chain variable region having an amino acid sequence of SEQ ID NO: 131; and
an antibody comprising a heavy-chain variable region having an amino acid sequence of SEQ ID NO: 128 and a light-chain variable region having an amino acid sequence of SEQ ID NO: 132.

### Claim 3 (depends on 1)

An antibody-drug conjugate comprising the antibody of claim 1 attached to a drug, wherein the drug is any one selected from the group consisting of a toxin, a chemotherapeutic agent, an anticancer drug, an antibiotic, ADP-ribosyl transferase, a radioactive isotope and a nucleolytic enzyme.

### Claim 4 (depends on 1)

A diagnostic kit for angiogenesis-related disease, comprising the antibody of claim 1.